公开(公告)号：US11865144B2

公开(公告)日：2024-01-09

申请号：US16052285

申请日：2018-08-01

申请人： Northwestern University

发明人： Jonathan F. Anker ,  Praveen Thumbikat ,  Sarki A. Abdulkadir ,  Anthony J. Schaeffer

IPC分类号： A61K35/74 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28 ,  A61K39/108 ,  A61K39/395

CPC分类号： A61K35/74 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/0258 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/523 ,  A61K2039/585 ,  A61K2039/884 ,  C12N2740/16043 ,  A61K39/3955 ,  A61K2300/00 ,  A61K39/0258 ,  A61K2300/00

摘要： Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

公开(公告)号：US11833196B2

公开(公告)日：2023-12-05

申请号：US17501576

申请日：2021-10-14

申请人： The Regents of the University of Michigan

发明人： James J. Moon ,  Rui Kuai ,  Anna A. Schwendeman ,  Jutaek Nam

IPC分类号： A61K39/00 ,  A61K47/69 ,  A61K9/127 ,  A61K31/713 ,  A61K47/54 ,  A61K31/712 ,  C12N15/11 ,  A61K31/7088 ,  A61K45/06 ,  C12N15/113

CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K39/00111 ,  A61K39/001106 ,  A61K39/001132 ,  A61K39/001151 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001176 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K45/06 ,  A61K47/554 ,  A61K47/6917 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3515 ,  C12N2320/32

摘要： The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).

公开(公告)号：US11712469B2

公开(公告)日：2023-08-01

申请号：US16847059

申请日：2020-04-13

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER

发明人： Christopher C. Kloss ,  Michel Sadelain

IPC分类号： A61K39/395 ,  C12N5/0783 ,  C07K14/705 ,  A61K39/00 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  A61K39/44 ,  A61K35/15 ,  C12N9/24

CPC分类号： A61K39/39558 ,  A61K35/15 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/00117 ,  A61K39/00118 ,  A61K39/001102 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001113 ,  A61K39/001114 ,  A61K39/001117 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001128 ,  A61K39/001129 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001171 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001193 ,  A61K39/001195 ,  A61K39/44 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3069 ,  C12N5/0638 ,  C12N9/2402 ,  A61K2039/5156 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/33 ,  C07K2319/74 ,  C12N2510/00 ,  C12N2999/002

摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

公开(公告)号：US11690910B2

公开(公告)日：2023-07-04

申请号：US16555881

申请日：2019-08-29

申请人： CureVac SE

发明人： Patrick Baumhof ,  Thomas Kramps ,  Söhnke Voss ,  Karl-Josef Kallen ,  Mariola Fotin-Mleczek

IPC分类号： A61K39/385 ,  A61K39/39 ,  A61K39/12 ,  A61K39/00 ,  A61K47/64 ,  A61K39/145 ,  A61K39/205 ,  A61K39/29 ,  A61K39/35 ,  A61K48/00 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/0011 ,  A61K39/00117 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001135 ,  A61K39/001151 ,  A61K39/001153 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/12 ,  A61K39/145 ,  A61K39/205 ,  A61K39/29 ,  A61K39/35 ,  A61K47/645 ,  A61K47/646 ,  A61K48/0041 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6093 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12N2730/10134 ,  C12N2730/10171 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2760/20134 ,  C12N2760/20171 ,  Y02A50/30

摘要： The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.